NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bushu Pharma Recognized with Frost & Sullivan’s 2023 Japan Customer Value Leadership Award for Offering Advanced Pharmaceutical Manufacturing - Bushu Pharma produces high-quality pharmaceutical and medical devices with sophisticated quality control and supply chain management support that prioritizes customer value - Bushu-Pharma.com
Bushu Pharma Recognized with Frost & Sullivan’s 2023 Japan Customer Value Leadership Award for Offering Advanced Pharmaceutical Manufacturing

 

NewswireTODAY - /newswire/ - San Antonio, TX, United States, 2023/11/30 - Bushu Pharma produces high-quality pharmaceutical and medical devices with sophisticated quality control and supply chain management support that prioritizes customer value - Bushu-Pharma.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Frost & Sullivan recently researched the contract development and manufacturing organization industry and, based on its findings, recognizes Bushu Pharma with the 2023 Japan Customer Value Leadership Award. Bushu Pharma is a market-leading contract manufacturing organization specializing in end-to-end pharmaceutical development, manufacturing, and supply chain management (SCM) solutions.

Bushu Pharma sets itself apart by delivering world-class manufacturing expertise to worldwide drug innovators, meeting current stringent Good Manufacturing Practice (GMP) standards on a clinical and commercial scale. With over two decades of expertise, the company is well-established in the Japanese contract pharmaceutical services market and has an impressive track record of exporting drugs to over 56 countries with several globally accredited GMP certifications.

To further increase its expansion in the Asian market, in 2021, the company launched its state-of-the-art solution, Gateway to Asia (GTA). This solution enables Bushu Pharma to be a central hub in Asia, handling bulk products in Japan for final packaging and timely shipment to multiple countries in the region. Moreover, GTA ensures major competitive advantages for Bushu Pharma’s customers, such as enhanced product quality, fast deliveries, shorter lead times, precise temperature and humidity controls, and a greatly reduced burden in the handling of urgent orders.

“With extensive experience as a contract development and manufacturing organization (CDMO), Bushu Pharma serves as a gateway to Asian markets. With a remarkable track record of 25 years as a CDMO and an impressive clientele of 90 commercial customers, the company has obtained GMP certifications in more than 40 countries,” said Azza Fazar, best practices research analyst at Frost & Sullivan.

Bushu Pharma goes beyond its extensive expertise and industry-leading capabilities by delivering unrivaled customer service. This allows the company to build a strong reputation in the industry and maintain a loyal customer base that grows steadily.

The company also takes a unique approach to its technology, product, and service development. It promotes close collaboration with relevant stakeholders and partners, helping Bushu Pharma rapidly adapt to dynamic market needs and trends. This approach differentiates the company from its closest competitors and facilitates the creation of pioneering solutions that perfectly address the ever-evolving challenges and emerging opportunities in the pharmaceutical industry.

“Bushu Pharma’s reputation has attracted diverse new customers, expanding its already established client base. For example, the company successfully secured partnerships with several multinational pharmaceutical firms, further supporting its growth trajectory. It projects sales for 2023 exceeding 35 million JPY, testifying to its success and indicating a solid financial performance and continued success in the pharmaceutical industry,” noted Surbhi Gupta, senior industry analyst at Frost & Sullivan.

Each year, Frost & Sullivan presents this award to the company that demonstrates excellence in implementing strategies that proactively create value for its customers, focusing on improving the return on the investment that customers make in its services or products. The award recognizes Bushu Pharma’s unique focus on augmenting its customers’ value, beyond simply good customer service, leading to improved customer retention and customer base expansion.

Frost & Sullivan Best Practices Awards (frost.com) recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Bushu Pharma

As one of the leading contract manufacturers of pharmaceutical products in Japan, Bushu Pharma (bushu-pharma.com) offers a broad range of optimal solutions for technology transfer, pharmaceutical production, packaging, and logistic services based on 25 years of experience and expertise as a CDMO* in all phases of development, from R&D projects for pharmaceuticals such as solid dosage formulations, primary packaging of solid dosage forms, production of injectable solutions, and more, to marketing approval of new drugs.

*CDMO (Contract Development Manufacturing Organization): A business that offers comprehensive services of manufacturing and development of pharmaceuticals, including the manufacturing of investigational drugs in the development stage as well as finished pharmaceutical products, and optimization of manufacturing processes on a contract basis for the pharmaceutical and biotechnology industries.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bushu Pharma Recognized with Frost & Sullivan’s 2023 Japan Customer Value Leadership Award for Offering Advanced Pharmaceutical Manufacturing

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan | Bushu Pharma
Contact: Tammy Chan - Frost.com 
877-463-7678 tammy.chan[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab & hyaluronidase-nvhy) Injection
NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1
SCHOTT Pharma Unveils Innovative Nest Design for Ready-to-use Cartridges
Ipsen and Biomunex Announce Exclusive Global Licensing Agreement for First-in-class MAIT Cell Engager in Immuno-oncology
Bushu Pharma Applauded by Frost & Sullivan for Offering Customer Value in APAC CDMO Industry through Consistent Quality Assurance, On-time Delivery
Bylvay® (odevixibat) Data Shows Sustained Improvement in Severe Itch and Serum Bile Acid Levels in Patients with PFIC and ALGS
Genome BC, STEMCELL Technologies and UBC Partner to Accelerate the Ability to Develop Stem Cells
PathogenDx Applauded by Frost & Sullivan for Enabling Early and Precise UTI Diagnosis with its Microarray Detection Platform
BASF Partners with Acies Bio to Drive Sustainable Production of Personal and Home Care Ingredients
Ipsen’s Kayfanda® (odevixibat) Approved in European Union for Cholestatic Pruritus in Alagille Syndrome, A Rare Liver Disease
STEMCELL Technologies and Axion BioSystems Partner to Streamline Culture and Analysis of Excitable Cells
Frost & Sullivan Awards Avance Clinical for Global Biotech CRO Excellence, Highlighting Agility, Responsiveness, Customer Value
BASF Declares Force Majeure for Selected Vitamin A, Vitamin E, and Carotenoid Products As Well As Selected Aroma Ingredients
Ono Pharmaceutical Co., Ltd Enters into A New Option and Research Collaboration Agreement with Monash University
Aragen Life Sciences Ltd Receives the 2024 Global Customer Value Leadership Award from Frost & Sullivan for Pioneering Excellence in Drug Discovery

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2005-2025 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)